Lupin Acquires VISUfarma to Grow Eye Health Segment in Europe

Global pharmaceutical giant Lupin Limited disclosed that its wholly owned subsidiary, Nanomi B.V., has executed a definitive agreement to acquire VISUfarma B.V., a specialty eye health company backed by GHO Capital Partners.

This acquisition represents an important step in Lupin’s strategy to build its European presence and expand its global specialty business in Eye Care.

With this acquisition, Lupin will obtain direct access into the fast-growing ophthalmology market, bolstered by an aging population, increasing diabetes-related conditions of the eye, and a heightened focus on preventive care.

VISUfarma has a strong presence in Europe with operations in Italy, the UK, Spain, Germany, and France, and offers a portfolio of over 60 branded ophthalmic products.

Also Read: Role of Optical Imaging in Early Cancer Detection and Treatment

Vinita Gupta, CEO of Lupin, stated that it is "immediately accretive" to Lupin, and will enhance the Company's specialty franchise, particularly in ophthalmology. The combined business will provide treatments across dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and targeted nutraceuticals prescribed by specialists.

Andrea Ponti, managing partner and Mike Turner, partner at GHO Capital, added, “Working closely with the VISUfarma management team, GHO Capital has transformed the company from a domestic Italian ophthalmic player into a unique pan-European business … partner to help grow VISUfarma further and leverage its strengths to build a global ophthalmology franchise.”

Lupin intends to use its cash reserves to fund the acquisition, which is expected to close no later than the end of 2025, pending regulatory conditions. VISUfarma has grown to become a pan-European leader in ophthalmology since 2016 under the ownership of GHO Capital.

Paolo Cioccetti, CEO Italy of VISUfarma, said that being part of Lupin has opened up a new chapter and is building a platform to develop a global ophthalmology franchise focused on innovation and patient outcomes.